Introduction and scope
Galderma Laboratories, L.P. and any other Galderma SA’s US affiliates [LR1] (hereinafter “Galderma”, “We”, “Us”) are responsible for the collection and processing of your data as they relate to cookies used in this website.
The Policy uses the term ‘cookies’ to refer to cookies and similar technologies covered by the law (such as, for example, Local Shared Objects – commonly referred to as “flash cookies”, web beacons or bugs, including transparent clear gifs). The gathered information concerns data that could allow to identify web users/visitors by associating and processing them with other data kept by third parties (such as, for example, the IP address, domain and registration numbers of the computers used by people connecting to the website). These data are used and processed only for statistical purposes.
1. WHAT IS A COOKIE?
A cookie is a small file, typically consisting of letters and numbers, downloaded on to a device when the user accesses the website. Cookies are text files that are placed on your computer by websites that you visit. Cookies are then sent back to the originating website on each subsequent visit, or to another website that recognises that cookie. Cookies contain information that is transferred to your computer’s hard drive. This information might be about you, your preferences or your device and is typically used to make the site work as you expect it. They are used in order to make websites work, or work more efficiently, as well as to provide information to the owners of the website.
Cookies are useful because they improve the website’s functionality and overall performance and provide the users with a more personalized experience. They also give insights on the use of our website by our visitors and help Us to understand how visitors are using our website and the services provided therein.
2. WHAT ARE THE TYPES OF COOKIES?
- Session and persistent cookies
Cookies can expire at the end of a browser session (from when a user opens the browser window to when they exit the browser) or they can be stored for longer periods of time.
Session cookies expire after a browser session. Session cookies allow websites to link the actions of a user during a browser session. They may be used for a variety of purposes such as remembering what a user has put in their shopping basket as they browse around a site. They could also be used for security when a user is accessing internet banking or to facilitate use of webmail. Their use is strictly limited to the purpose of transmitting data (made up of random numbers created by the server) identifying the specific session and necessary to allow a safe and efficient website surfing by avoiding any other computer methods that could potentially compromise the users’ privacy.
Persistent cookies are stored persistently on a users’ device in between browser sessions. Persistent cookies allow the preferences or actions of the user across a site (or in some cases across different websites) to be remembered. Persistent cookies may be used for a variety of purposes including remembering users’ preferences and choices when using a site.
- First and third-party cookies
Cookies can be classified as ‘first’ or ‘third’ party depending on the website or domain placing the cookie.
First party cookies in basic terms are cookies set by the domain visited by the user – the website displayed in the URL window: i.e., cookies set by Galderma on this website.
Third party cookies are cookies that are set by a domain other than the one being visited by the user: i.e., cookies, which are set by companies and web sites other than Galderma, such as Google, Facebook, YouTube etc.
3. WHAT CATEGORIES OF COOKIES ARE USED ON THIS WEBSITE?
We use the following categories of cookies:
4. MANAGE YOUR COOKIE PREFERENCES
Some cookies are strictly necessary for the correct functioning of this website and do not require user’s consent, such as those ensuring that the content of a page loads quickly and effectively by distributing the workload across numerous computers or else those providing security.
Other cookies are still reasonably necessary or important, but they are not strictly essential and, therefore, require user’s consent. For these cookies (i.e. performance and functionality, advertising/targeting), you can opt out before placing them on your device.
You may access and change your cookie preferences clicking at the bottom left corner of the website.
Additionally, if you wish to withdraw your consent to any non-essential cookies at any time, you will need to delete, and block or disable cookies via your browser settings. These settings are usually found in the ‘options’ or ‘preferences’ menu of your internet browser. Otherwise, you should use the ‘help’ option in your internet browser for more details or you can click on one of the links below to go directly to the user manual for your browser:
Alternatively, you may wish to visit www.aboutcookies.org (link is external), which contains comprehensive information on how to do this on a wide variety of desktop browsers, or the following sites: http://www.aboutads.info/choices/#completed or http://www.youronlinechoices.eu/
Please note that disabling or blocking some or all of the categories of cookies will affect the functionality of the website and may impact your access and experience with our website and the services we are able to offer.
5. POLICY UPDATE
We reserve the right to make any changes and corrections to this Policy. Please refer to this page from time to time to review these and new additional information. We will place updates on Galderma Sites and, where appropriate, we will notify of any changes by email.
Important Safety Information
Indication: TRI-LUMA® (ﬂuocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream is indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face in the presence of measures for sun avoidance, including the use of sunscreens. Adverse Events: In the controlled clinical trials, the most frequently reported events were redness, peeling, burning, dryness, and itching at the site of application. Warnings/Precautions: TRI-LUMA Cream contains sulﬁtes which may cause severe, life-threatening allergic reactions in people allergic to sulﬁtes. TRI-LUMA Cream contains hydroquinone, which may cause a gradual blue-black darkening of the skin. If you are pregnant, nursing or trying to become pregnant you should not use TRI-LUMA Cream. Safety and efficacy have not been established in individuals with darker skin. Reversible HPA axis (adrenal function) suppression may result from exposure to the topical corticosteroid, ﬂuocinolone acetonide, so discontinue use if signs and symptoms of this condition occur. Avoid products that may dry or irritate the skin, such as abrasive cleansers, scrubs, or skin-peeling agents. Exposure to sunlight, sunlamps, or UV light and extreme heat, wind, or cold should be avoided. If exposure cannot be avoided, sunscreen products [SPF 30 or more] and protective apparel should be used.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
- TRI-LUMA (ﬂuocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream [Prescribing Information]. Dallas, TX: Galderma Laboratories, L.P.; 2014.
- Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67-72.
- Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013 Oct;169 Suppl 3:41-56. doi: 10.1111/bjd.12536. PMID: 24098900.
- Ogbechie-Godec OA, ElbuluK N. Melasma: an up-to-date comprehensive review. Dermalol Ther (Heidelb). 2017;7(3):305-318. doi:10.10071/s13555-017-0194-1.
- “Melasma.” American Academy of Dermatology Public Resource Center. TRI-LUMA (ﬂuocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream.
- Grimes P, Watson J. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%. Cutis. 2013;91(1):47-54.
- Ference JD, Last AR. Choosingtopical corticosteroids. Am Fam Physician. 2009;79(2):135-140. 8. Kagha K, Fabi S, Goldman MP. Melasma’s impact on quality of life.J Drugs Dermatol. 2020;19(2):184-187. doi:10.36849/ JDD.2020.4663.
- Kagha K, Fabi S, Goldman MP. Melasma’s impact on quality of life.J Drugs Dermatol. 2020;19(2):184-187. doi:10.36849/ JDD.2020.4663.